FutureLife Group expands its network within Romania with Acquisition of Gynatal in Timisoara

Prague/Timisoara, 19th November 2024 – FutureLife, a leading pan-European provider of IVF and genetics services, performing more than 55,000 IVF cycles annually and backed by CVC Capital Partners (‘CVC’) and Hartenberg Holding (‘Hartenberg’), is pleased to announce the acquisition of Gynatal, a respected fertility clinic in Timisoara, Romania. Located in the western part of the country, Timisoara is a key economic and cultural hub. This acquisition marks FutureLife’s continued expansion into Romania, building on the company’s purchase of Gynera, a premium fertility clinic in Bucharest, in June 2019 and the Cytogenomic Medical Laboratory, Bucharest which provides a full range of services in clinical and molecular genetics, cytogentics and prenatal screening.

Founded in 2004 and accredited for IVF in 2009, Gynatal has been a trusted provider of comprehensive fertility services for two decades, with well established expertise in embryology and the first Embryologist to perform IVF in Romania. The clinic offers private treatments and those funded by public programmes, ensuring access to high-quality fertility care for a broad range of patients. Gynatal provides services for every stage of the IVF process plus specialised care in nutrition and psychology.

Francisco Lobbosco, CEO of FutureLife, said:

“We are excited to welcome Gynatal into the FutureLife family. With its strong reputation for clinical excellence and personalised care, Gynatal is a perfect fit for our growing network. Following our acquisition of Gynera in Bucharest, the addition of Gynatal strengthens our position in Romania, allowing us to offer top-tier reproductive services across both major regions. Whether privately funded or supported through public programs, we remain committed to making high-quality fertility care accessible to more families.”

“Our strategy continues to focus on harmonizing best practices across all FutureLife clinics while preserving the local expertise that makes each clinic unique. With Gynatal’s deep understanding of patient needs in Timisoara and our international resources, we are confident that together we can continue to deliver excellent outcomes and tailored treatments.”

Dr Florin Dorneanu, Medical Director of Gynatal, commented:

“Joining FutureLife represents a major step forward for Gynatal. Since 2004, we have been dedicated to offering high-quality fertility services, and with FutureLife’s support, we can now expand our capabilities and serve even more patients. By combining our local knowledge with the backing of an international leader in reproductive medicine, we are well-positioned to continue providing exceptional care both privately and through Ministry of Family supported programmes.”

About FutureLife 

FutureLife is one of the leading European providers of IVF, fertility treatments and related genetic services. With 40+ well-invested clinics, in 8 countries, employing more than 1,500 specialists performing in excess of 55,000 IVF cycles annually, as well as a series of gynaecological and surgical treatments.
In addition to its clinic and hospital portfolio FutureLife operates the GNT Lab, one of the largest and most modern genetic laboratories in Europe and enables the group to meet the demand for genetic services with speed and efficiency, raising the level of care provided to the group’s patients. 
The team at FutureLife believe in a world where everyone has the freedom to create a family and adopt an evidence-based approach to the innovation of treatment strategies, with a mission statement focused on ethics and standards. 
The group is also focused on additional acquisitions in a number of other key European geographies and announced the acquisition of BCRM, Bristol, UK in October 2024.

FutureLife is co-owned by CVC and Hartenberg. www.futurelifegroup.com

Press contacts 

For FutureLife:

Jane Exon

pressoffice@futurelifegroup.com